The fusion of an immunogenic peptide and the protein transthyretin protects the peptide antigen from proteolytic degradation, optimizes its uptake in local draining lymphatics and reduces its presentation in uninflamed distal lymphoid organs, as shown in mice.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Rammensee, H. G., Falk, K. & Rotzschke, O. Annu. Rev. Immunol. 11, 213–244 (1993).
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Proc. Natl Acad. Sci. USA 93, 7855–7860 (1996).
Mehta, N. K. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-0563-4 (2020).
Francis, M. J. et al. Proc. Natl Acad. Sci. USA 87, 2545–2549 (1990).
Janssen, R. & Tommassen, J. Int. Rev. Immunol. 11, 113–121 (1994).
Suzue, K. & Young, R. A. J. Immunol. 156, 873–879 (1996).
Mu, X. et al. J. Virol. Methods 228, 84–90 (2016).
Botelho, N. K. et al. Front. Immunol. 10, 294 (2019).
Ishihara, J. et al. Sci. Transl. Med. 9, eaan0401 (2017).
Wille-Reece, U. et al. Proc. Natl Acad. Sci. USA 102, 15190–15194 (2005).
Zom, G. G., Khan, S., Filippov, D. V. & Ossendorp, F. Adv. Immunol. 114, 177–201 (2012).
Kim, S. et al. Nat. Rev. Mater. 4, 355–378 (2019).
P.R. is a member of the scientific advisory board of immatics biotechnologies GmbH. J.A.H. is co-founder of Arrow Immune, Inc., and through his university holds patents in immuno-oncology. The remaining author declares no competing interests.
About this article
Cite this article
Romero, P., Donda, A. & Hubbell, J.A. An optimized antigen–protein fusion. Nat Biomed Eng 4, 583–584 (2020). https://doi.org/10.1038/s41551-020-0572-3